Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™

NCT00058747 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT00058747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00058747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2003
Completion date
April 30, 2006
Enrollment
40
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, chronic